Surrenti R&D in novatione coviD-19 feruntur, curationes cancer, plenae doloris imperium et morborum autoimmunem.

Clavis Programs	indication	Preclinical	tempus te	Phase II	Phase III/Pivotal	FDA Approval
Covid-19 Programs
COVISTIX™ (diagnostic) Celeri Antigen Test 0%* Subitis Usus LICENTIA (EUA) in Mexico (COFEPRIS), Brasilia (ANVISA), CE Signata in Europa COVIMARK™ (diagnostic) Celeri Antigen Test 0%* Applicationem summitto in US et in Canada ad tumultuarios usus LICENTIA (EUA) VIREX (diagnostic) Apud Home Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS ex COVID-19 in ICU aegroti 82%* Pivotal Trial in Brasilia                           OVYDSO (Olgotrelvir) Anti-virales (Oral Pill) 40%* Omicron mRNA Vaccine vaccine 20%*
Clavis Programs	indication	Preclinical	tempus te	Phase II	Phase III/Pivotal	FDA Approval
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) prostatae 20%* PD-L1 (Socazolimab)* SCLC 82%* * In societate cum Lee Pharm in China PD-L1 (STI-3031)** Ceruicis cancer 82%* ** In US et in societate cum ImmuneOncia in Korea CD47 solidus Tumors 40%* CD38 DAR-T Herpesvirus multiple 40%* CD38 ADC Amyloidosis, Myeloma multiplex, T-ALL, et gulae 40%* TROP2 ADC* solidus Tumors 40%* Seprehvec™ virus oncolyticum Solidi tumores; CNS Tumors 40%* BCMA ADC Liquid Tumors 20%* Bevacizumab-ADNAB™ Cancer endometrialis 40%* In societate cum Mayo Clinic Bevacizumab-ADNAB™ ovarian cancer 40%* In societate cum Mayo Clinic Rituximab-ADNAB™ B-cellula Lymphomas 40%* In societate cum Mayo Clinic Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Clavis Programs	indication	Preclinical	tempus te	Phase II	Phase III/Pivotal	FDA Approval
Phau:
ZTlido® 1.8% Postherpetica Neuralgia - PHN 99.8%* Gloperba® Curatio Podagra (Oral) 99.8%* SEMDEXA (SP-102) Radicularis lumborum / Dolor Ciatica 82%* SP-103 (Lidocaine Topical System 5.4%) Acutus Back Pain 60.2%* SP-104 (Burst Dilatio Minimum Dose Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Iniectio epiduralis Dolor intractabilis in Cancer Advanced 60.3%* Pupillus designatio RTX (resiniferatoxin) Iter intra-articular Moderari ut Gravi genu OA Dolor 60.2%*
Clavis Programs	indication	Preclinical	tempus te	Phase II	Phase III/Pivotal	FDA Approval
Lymphatica medicamentis Delivery
Sofusa® TNF anti- Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Carcinoma 40%* In societate cum Mayo Clinic

Covid-19 Programs
Clavis Programs (Indicatio)	tempus
COVISTIX™ (diagnostic) FDA EUA COVIMARK™ (diagnostic) FDA EUA VIREX (diagnostic) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA Vaccine Preclinical

immunotherapy
Clavis Programs (Indicatio)	tempus
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Preclinical PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031) Ph III CD47 (Solidi tumores) Ph I CD38 DAR-T (Multiplex Myeloma) Ph I CD38 ADC (Amyloidosis, Myeloma multiplex, T-ALL, et oesophagealis) Ph I TROP2 ADC* (Solidi tumores) Ph I Seprehvec™ virus oncolyticum (Solidi tumores; CNS Tumors) PH I BCMA ADC ( Liquida tumores ) Preclinical Bevacizumab-ADNAB™ (Cancer endometrial) Ph I Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Phau:
Clavis Programs (Indicatio)	tempus
ZTlido® 1.8% (Postherpetica Neuralgia - PHN) FDA Approval Gloperba® 1.8% Curatio Podagra (Oral) FDA Approval SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Burst Dilatio Minimum Dose Naltrexone) Preclinical RTX (resiniferatoxin) Iniectio epiduralis Ph II RTX (resiniferatoxin) Iter intra-articular Ph II

Lymphatica Delivery
Clavis Programs (Indicatio)	Phase II
Sofusa® TNF anti- (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Carcinoma) Ph I